Brief: Redx Pharma PLC Says Loss For FY Period Of £33.2 Mln

Redx Pharma

15/12/2023 07:26

Dec 15 (Reuters) - Redx Pharma PLC  REDX.L :
    * REDX PHARMA PLC - ZELASUDIL ENTERS PHASE 2A CLINICAL
PROGRAMME
IN IPF AND DELIVERS COMPELLING PRECLINICAL DATA IN OTHER
FIBROTIC INDICATIONS
    * REDX PHARMA PLC - SECURED A £14.1 MILLION EQUITY FINANCING
WITH
EXISTING INSTITUTIONAL INVESTORS WHICH EXTENDS OUR CASH RUNWAY
INTO Q3 2024
    * REDX PHARMA PLC - CASH BALANCE AT 30 SEPTEMBER 2023 OF
£18.1
MILLION (30 SEPTEMBER 2022 £53.9 MILLION)
    * REDX PHARMA PLC -  LOSS FOR FY PERIOD OF £33.2 MILLION (FY
2022
£18.0 MILLION)
    * REDX PHARMA PLC - CONFIRM SUBMISSION OF A CTA FOR OUR
SECOND
ROCK ASSET, RXC008, FOR WHICH WE EXPECT TO COMMENCE A PHASE 1
STUDY EARLY IN 2024

Source text for Eikon:  ID:nRSO9116Wa 
Further company coverage:  REDX.L 

 ((Reuters.Briefs@thomsonreuters.com;))